CombinatoRx Presents Full Data On Synavive Phase 2 Knee OA Trial At EULAR 2009
CombinatoRx, Incorporated (NASDAQ: CRXX) announced the presentation of full data on Synavive (CRx-102) Phase 2 knee osteoarthritis (OA) trial (COMET-1) at EULAR 2009, the Annual European Congress of Rheumatology in Copenhagen on June 12, 2009. The presentation, “CRx-102, a dissociated glucocorticoid (GC), and prednisolone provide safe and effective pain relief in knee osteoarthritis (OA) in a placebo-controlled Phase 2 trial (COMET-1)”, Huttner et.al.
More: continued here
Filed under: Bones on June 19th, 2009
You must be logged in to post a comment.